Carbonic anhydrase inhibitors against cerebrovascular dysfunction in Alzheimer's disease and dementias

Key Points

• Cerebrovascular dysfunction improves with carbonic anhydrase inhibitors, indicating their potential in treating Alzheimer's disease.
• Evidence comes from biomarkers reflecting neurodegeneration in dementia patients showing notable changes after intervention.
• Analysis of cerebrovascular responses to carbonic anhydrase inhibitors reveals their significant role in managing Alzheimer's-related dysfunction.
• These findings support further investigation into cerebrovascular targeting for therapies in neurodegenerative conditions like Alzheimer's.